Adocia is a clinical‐stage biopharmaceutical company headquartered in Lyon, France, specializing in the development of innovative therapeutic solutions for diabetes and other metabolic diseases. The company’s core expertise lies in the formulation of protein‐based drugs, with a primary focus on insulin analogs and GLP‐1 receptor agonists. Adocia’s BioChaperone® platform enables the precise engineering of pharmaceutical properties—such as absorption rate, stability and bioavailability—thereby improving the pharmacokinetic and pharmacodynamic profiles of peptide therapeutics.
The BioChaperone® technology has been applied to a range of product candidates in Adocia’s pipeline. These include rapid‐acting insulins designed to more closely mimic physiological insulin secretion, ultra‐long‐acting basal insulins for once‐daily use, and fixed‐ratio combinations that merge insulin and GLP‐1 activity in a single formulation. Several of these candidates are in various stages of clinical development, with data indicating potential benefits in glycemic control, hypoglycemia risk reduction and patient convenience compared to existing therapies.
Since its founding in 1999, Adocia has cultivated collaborations with major pharmaceutical and biotechnology firms, further validating its platform’s versatility and commercial potential. The company’s licensing agreements and joint development partnerships span Europe, North America and Asia, reflecting a global strategy to bring next‐generation diabetes treatments to market. Adocia’s management team, led by CEO François Florence, combines deep experience in drug development, regulatory affairs and commercial strategy, positioning the company to advance its product candidates through late‐stage clinical trials and potential commercialization.
Adocia is publicly traded on the OTC Markets under the ticker ADOCY, offering international investors exposure to a specialized biotech firm dedicated to addressing the growing global burden of diabetes and metabolic disorders. The company continues to invest in research and development, aiming to expand its pipeline beyond diabetes into complementary therapeutic areas where its BioChaperone® platform can add value.
AI Generated. May Contain Errors.
